In its latest raft of advice, the Scottish Medicines Consortium (SMC), Scotland’s health technology appraisal body, has accepted UCB’s potential mega blockbuster psoriasis drug Bimzelx (bimekizumab) for use on the Scottish National Health Service following a fast-track process.
The SMC made a restricted recommendation for Bimzelx for plaque psoriasis patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy) or are intolerant of,...